Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target
Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and maintains $30 price target.
An analyst who watches Intellia Therapeutics says the company should do better than the overall market and keeps their prediction at $30 per share. When experts keep their positive views steady, it can suggest they still believe in the company's plan and progress.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.